Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
CTLA-4 Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 40+ Leading Players Wheeling the Therapeutics Segment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: PR Newswire Association LLC. - 31 May 2023 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The CTLA-4 inhibitors pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis. LAS VEGAS, May 31, 2023 /PRNewswire/ -- DelveInsight's 'CTLA-4 Inhibitors Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline CTLA-4 inhibitors in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the CTLA-4 inhibitors competitive domain. Key Takeaways from the CTLA-4 Inhibitors Competitive Landscape Report
Request a sample and discover the recent advances in CTLA-4 inhibitors @ CTLA-4 Inhibitors Competitive Landscape Report CTLA-4 Inhibitors Overview CTLA-4 (cytotoxic T lymphocyte antigen-4) is a key negative regulator of T cell activation. The well-defined B7:CD28/CTLA-4 pathway controls the production and maintenance of immune responses through a complex integration of positive and negative co-stimulatory signals. Inhibiting negative regulation via CTLA-4 binding has been demonstrated to increase adaptive immunity stimulation and T cell activation potentiation. CTLA-4-blocking antibodies have shown efficacy as monotherapy in several murine malignancy models; additionally, they have shown synergistic anti-tumor action when combined with other treatments such as vaccinations, chemotherapy, and radiation. T cell activation necessitates not only stimulation of the T cell receptor (TCR) on antigen-presenting cells (APCs) by peptide-major histocompatibility complexes (MHCs) but also an orchestrated balance of co-stimulatory and inhibitory signals that modulate the magnitude and effectiveness of the immune response. Multiple mechanisms control the activation of effector CD4+ and CD8+ T lymphocytes (Teffs), including cell surface proteins that augment or suppress T cell responses. Negative regulatory proteins on T cells, including CTLA-4, PD-1, B7 family member B7-H4, T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3), and lymphocyte activation gene-3 (LAG-3), interact with their cognate ligands on a variety of cell types, including APCs, regulatory T cells (Tregs), and nonhematopoietic cells, resulting in decreased T cell proliferation and functional activity. Find out more about CTLA-4 inhibitors drugs @ CTLA-4 Inhibitors Analysis CTLA-4 Inhibitors Pipeline Analysis: Drug Profile KN046: Alphamab Oncology Jiangsu Alphamab developed KN046 as an independent PD-L1/CTLA-4 bispecific antibody. Its new designs include: a CTLA-4 domain combined with a PD-L1 single-domain antibody; tailored to target the tumor microenvironment with high PD-L1 expression; and Treg inhibits tumor immunity-clearing activity. In Australia and China, there are over 20 clinical trials using KN046 in various phases covering more than ten types of tumors including NSCLC, thymic cancer, pancreatic cancer, HCC, ESCC, and TNBC. The outcomes of these clinical trials have revealed good data in terms of patient survival. Based on the clinical outcomes in China and Australia, Alphamab Oncology has acquired FDA approval to begin later-stage trials of KN046. Furthermore, KN046 has been granted orphan drug status by the US Food and medication administration for thymic epithelial tumor in September 2020. Four key clinical trials are presently underway. The drug is currently in Phase III development for the treatment of Squamous Non-small-cell Lung Cancer. IBI-310: Innovent Biologics IBI-310 is under development for the treatment of advanced, recurrent, or metastatic non-small-cell lung cancer(NSCLC), unresectable or relapsed or metastatic advanced Biliary tract cancer, metastatic solid tumors including advanced hepatocellular carcinoma, recurrent and metastatic nasopharyngeal carcinoma, acral melanoma, liver cancer, cervical cancer, renal cell carcinoma, EBV-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The medication candidate is delivered intravenously. It works by interacting with the cytotoxic T-lymphocyte protein 4 receptor (CTLA4). It was also being studied as a therapy for metastatic melanoma and metastatic colorectal adenocarcinoma. The medication is currently under Phase III clinical trial evaluation for the treatment of Hepatocellular Carcinoma. A snapshot of the CTLA-4 Inhibitors Pipeline Drugs mentioned in the report:
Learn more about the emerging CTLA-4 inhibitors pipeline drugs @ CTLA-4 Inhibitors Clinical Trials Scope of the CTLA-4 Inhibitors Competitive Landscape Report
Dive deep into rich insights for new CTLA-4 inhibitors drugs, visit @ CTLA-4 Inhibitors Drugs Table of Contents
For further information on the CTLA-4 inhibitors pipeline therapeutics, reach out @ CTLA-4 Inhibitors Therapeutic Assessment Related Reports PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others. PD-1 and PD-L1 Inhibitors Competitive Landscape PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others. JAK Inhibitors Competitive Landscape JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others. TIGIT Inhibitors Competitive Landscape TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Contact Us Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2023 PR Newswire Association LLC. | Back to overview list |